The Weight Loss Pill Boom: A Marketing Opportunity for Pharma Giants?
The UK's approval of Foundayo has sent shockwaves through the health industry, making it the first country in Europe to greenlight this treatment for both weight loss and type 2 diabetes.
This development raises questions about the pharmaceutical industry's marketing strategies. With an estimated 8. 25 million people in the UK already taking or considering GLP 1 weight loss medications, demand is high.